Corporate Presentation

Rapid Progress in Advancing SNA Programs in Neuroscience 1889 XCUR-FXN in IND-Enabling Studies for FA Rapid Clinical De-Risking Based on Increasing Frataxin Levels in CSF Two Additional CNS Programs Moving into Preclinical Studies SCN9A - Validated Pain Target CLN3 - PoC for Eye Disorders SCAS Batten Disease ALS Angelman Friedreich's Ataxia Deep CNS Discovery Pipeline SNA Therapeutics with Differentiating CNS Biodistribution and Persistence Further Active Programs Against Validated, Sought-After Targets exicure | 12

View entire presentation